DexCom (NASDAQ:DXCM) Price Target Cut to $90.00

DexCom (NASDAQ:DXCM) had its price target cut by Stifel Nicolaus from $132.00 to $90.00 in a research report sent to investors on Friday, Benzinga reports. They currently have a buy rating on the medical device company’s stock.

A number of other equities research analysts have also recently commented on DXCM. UBS Group lifted their price objective on DexCom from $153.00 to $163.00 and gave the stock a buy rating in a research note on Wednesday, April 10th. Redburn Atlantic started coverage on DexCom in a research note on Thursday, May 30th. They set a neutral rating and a $130.00 price objective for the company. Royal Bank of Canada decreased their price objective on DexCom from $165.00 to $145.00 and set an outperform rating for the company in a research note on Friday. Morgan Stanley decreased their target price on DexCom from $132.00 to $120.00 and set an equal weight rating for the company in a research note on Monday, July 15th. Finally, JPMorgan Chase & Co. cut DexCom from an overweight rating to a neutral rating and decreased their target price for the company from $145.00 to $75.00 in a research note on Friday. Seven equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of Moderate Buy and an average target price of $111.50.

DexCom Trading Up 5.4 %

DXCM stock opened at $67.48 on Friday. The company has a market cap of $27.04 billion, a P/E ratio of 43.54, a PEG ratio of 1.58 and a beta of 1.16. DexCom has a twelve month low of $62.34 and a twelve month high of $142.00. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00. The business has a fifty day moving average of $114.02 and a 200-day moving average of $123.33.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The business had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.04 billion. During the same period in the previous year, the firm earned $0.34 earnings per share. The firm’s quarterly revenue was up 15.3% compared to the same quarter last year. As a group, equities research analysts expect that DexCom will post 1.76 EPS for the current year.

Insider Transactions at DexCom

In related news, EVP Michael Jon Brown sold 652 shares of the company’s stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $119.24, for a total transaction of $77,744.48. Following the sale, the executive vice president now owns 67,560 shares in the company, valued at $8,055,854.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, EVP Sadie Stern sold 427 shares of the company’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $115.05, for a total transaction of $49,126.35. Following the sale, the executive vice president now owns 75,877 shares in the company, valued at $8,729,648.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael Jon Brown sold 652 shares of the company’s stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $119.24, for a total value of $77,744.48. Following the sale, the executive vice president now owns 67,560 shares in the company, valued at approximately $8,055,854.40. The disclosure for this sale can be found here. Insiders sold 3,483 shares of company stock valued at $401,450 over the last three months. Company insiders own 0.30% of the company’s stock.

Institutional Trading of DexCom

Several institutional investors and hedge funds have recently bought and sold shares of DXCM. Vanguard Group Inc. raised its stake in DexCom by 0.3% in the first quarter. Vanguard Group Inc. now owns 44,603,745 shares of the medical device company’s stock valued at $6,186,539,000 after buying an additional 136,282 shares during the period. Capital Research Global Investors raised its stake in DexCom by 21.4% in the fourth quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock valued at $1,898,085,000 after buying an additional 2,695,296 shares during the period. Sands Capital Management LLC raised its stake in DexCom by 10.2% in the fourth quarter. Sands Capital Management LLC now owns 15,058,806 shares of the medical device company’s stock valued at $1,868,647,000 after buying an additional 1,398,136 shares during the period. Capital World Investors raised its stake in DexCom by 130.7% in the fourth quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock valued at $1,151,392,000 after buying an additional 5,256,092 shares during the period. Finally, Artisan Partners Limited Partnership raised its stake in DexCom by 164.8% in the fourth quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock valued at $732,169,000 after buying an additional 3,672,471 shares during the period. Institutional investors own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.